Abstract 2929
Background
The human microbiome has been suggested to be involved in the regulation of response to anticancer strategies, however, information about how commensal microbes in a cancer patient change during radiotherapy is limited and the relationship between the microbiome and response to radiotherapy is poorly studied.
Methods
Sixty-two patients with nasopharyngeal carcinoma scheduled for radiotherapy-based treatment were prospectively enrolled. Nasopharyngeal swab samples were collected longitudinally during radiotherapy, and their microbial composition was assessed using 16S rRNA sequencing. All patients were followed up to 24 months after completion of radiotherapy.
Results
The beta-diversity of nasopharyngeal microbial communities (np-microbiome) showed changes throughout radiotherapy-based treatment. The magnitude of changes in the np-microbiome was stably and statistically significantly different between early and late responders (P = 0.02), with greater changes in early responders. This was confirmed in a temporal network analysis, where the networks varied widely in early responders, but were significantly more constrained in late responders (P = 0.009). Operational taxonomic units (OTUs) mapped to Corynebacterrium, Staphylococcus and Anaerococcus showed increasing loss with treatment, while all other abundant OTUs were stable over treatment. Twenty-seven abundant OTUs differed statistically, significantly (P < 0.05) by patients’ response throughout the treatment period.
Conclusions
The nasopharyngeal microbiome in NPC patients changes during radiotherapy-based treatment. These changes are statistically, significantly associated with patients’ response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society; Swedish Research Council; National Natural Science Foundation of China; China Scholarship Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract
2142 - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells
Presenter: Moon Hee Lee
Session: Poster Display session 3
Resources:
Abstract
5501 - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christine Chung
Session: Poster Display session 3
Resources:
Abstract
5726 - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.
Presenter: Francesca Sparano
Session: Poster Display session 3
Resources:
Abstract
2534 - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Presenter: Laurent Dercle
Session: Poster Display session 3
Resources:
Abstract
3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Presenter: FEIYU ZHANG
Session: Poster Display session 3
Resources:
Abstract
2089 - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model
Presenter: Changhua Ji
Session: Poster Display session 3
Resources:
Abstract
4463 - Effects of dietary restriction in cancer patients receiving irinotecan
Presenter: Ruben Van Eerden
Session: Poster Display session 3
Resources:
Abstract
4841 - Investigating the Link between Burn Injury and Tumorigenesis
Presenter: Lucy Barrett
Session: Poster Display session 3
Resources:
Abstract
4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
Presenter: Joanna Huszno
Session: Poster Display session 3
Resources:
Abstract